Approval · Notice of Compliance 5352 · 2004
VIRAMUNE: Notice of Compliance 5352
Issued September 13, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5352
- Date
- September 13, 2004
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Replaces the notice of compliance with conditions issued on september 4, 1998
- Therapeutic class
- Antiretroviral agent, non0nucleoside reverse transcriptase inhibitor with activity against human immunodeficiency virus type 1 (HIV-1)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIRAMUNE | Not yet assigned | — |
Medicinal ingredients
- NEVIRAPINE 200 MG per TAB